Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST) investors of a class action representing investors that bought securities between November 7, 2024 and July 8, 2025, inclusive (the "Class Period"). RxSight investors have until September 22, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Po ...

Core Viewpoint - RxSight, Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to its securities, indicating possible legal challenges ahead for the company [1] Company Summary - RxSight, Inc. is listed on NASDAQ under the ticker RXST [1] - The investigation is being conducted by Faruqi & Faruqi, a prominent national securities law firm with a history of recovering substantial amounts for investors [1] Legal Context - Faruqi & Faruqi has been operational since 1995 and has offices in New York, Pennsylvania, California, and Georgia [1] - The firm has successfully recovered hundreds of millions of dollars for investors, highlighting its experience and capability in handling securities-related claims [1]

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 8, 2025 /PRNewswire/ -- Berger Montague PC, a national securities litigation law firm announces it is investigating potential securities fraud claims involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST), following the recent filing of a federal securities class action lawsuit. Caitlin AdorniBerger Montague(267) 764-4865[email protected] SOURCE Berger Montague WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influ ...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit ...

Market Overview - The cataract market is the largest surgical market in the U.S. [2] - There has been a decrease in overall cataract surgeries at the beginning of the year, which is a notable trend not seen for a while [2] - Despite demographic trends suggesting low single-digit growth, the reasons for the decrease in surgeries remain unclear [3] Premium Segment Insights - The premium segment of the cataract market has shown more stability compared to the overall market [3] - The demographic for cataract surgery typically involves patients aged 60 and above [3]

Summary of the Conference Call Company and Industry Overview - The conference call involved RxSight, a company focused on the cataract surgery market, specifically in the U.S. [4][1] - The cataract market is identified as the largest surgical market, with a noted decrease in overall cataract surgeries at the beginning of the year, despite demographic trends suggesting growth [4][5] Key Insights and Arguments - **Market Trends**: There was a decrease in cataract surgeries, which was unexpected given demographic trends. This decline may be attributed to macroeconomic factors or psychological impacts from political changes [4][5] - **Patient Behavior**: Patients were reported to be postponing surgeries or opting for less expensive monofocal lenses instead of premium options, which continued into Q2 [5][7] - **Economic Factors**: The economic environment has significantly impacted the LASIK market, particularly affecting younger demographics, while the premium cataract market has shown more stability [7][8] - **Lens Preferences**: The preference for toric lenses has increased, as they provide better outcomes for patients with astigmatism. The trend is moving towards higher quality vision options [11][12] - **Demographic Shifts**: The mean age for cataract surgery has decreased over the past decade, indicating a younger demographic is increasingly opting for these procedures [12][13] Competitive Landscape - The introduction of new competitors in the premium intraocular lens (IOL) market has increased competition, with 25-30% of patients coming from multifocal patients who might have otherwise chosen premium lenses [37][38] - Private equity-backed ophthalmology practices represent about 20-30% of the market and are incentivized to convert patients to premium lenses, which benefits RxSight [20][21] Customer Engagement and Support - RxSight is focusing on improving customer support and training for new users of their Light Adjustable Lens (LAL) technology, recognizing the need for ongoing clinical support as practices evolve [25][26] - The company has restructured its sales force to better align clinical support with sales efforts, aiming to enhance customer experience and adoption rates [31][32] International Expansion - Approximately 80% of premium lenses are sold outside the U.S., with RxSight focusing on regulatory approvals in major economies in Europe and Asia [40][41] - The company is leveraging its U.S. experience to establish a presence in international markets, recognizing the global nature of ophthalmology [41][42] Financial Outlook and Market Position - RxSight has maintained a market share of about 10-11% in the premium IOL market, with expectations for growth driven by demographic trends and the increasing reliability of their products [47][48] - The company anticipates that the overall market for premium lenses will grow, supported by favorable reimbursement trends and the increasing demand for quality vision solutions [48][49]

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is from November 7, 2024, to July 8, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its sales and utilization, overstated demand for its products, and was unlikely to meet its financial guidance for fiscal year 2025 [4]. - The misleading statements led to investor damages when the true details about the company's performance were revealed [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [3][4]. Group 1: Allegations Against RxSight - The complaint alleges that RxSight and its executives made false or misleading statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [3]. - Specific issues cited include "adoption challenges" and structural problems leading to declines in sales and utilization, which were not disclosed to investors [3]. Group 2: Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [4]. - Following this announcement, RxSight's stock price dropped by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually high trading volume [4]. Group 3: Legal Proceedings - Investors who suffered losses in RxSight are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of September 22, 2025, to seek the role of lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].